Drug May Lead to 6% Weight-loss in Type-2 Diabetics
A clinical trial in Denmark has shed light on the fact that drug liraglutide can lead to weight loss in overweight or obese people with type-2 diabetes.
One of the authors at Novo Nordisk said after conclusion of the second phase, the drug can achieve 6% weight loss in overweight people. Company officials mentioned that second phase 3a trial is a part of the clinical development program for liraglutide 3 milligram as an obesity treatment.
Through the experiment almost 846 overweight or obese people with type 2 diabetes were followed. They were treated with liraglutide 3 mg, liraglutide 1.8 mg or placebo.
After a period of 56 weeks, the experiment ended and the subjects were tracked for a 12-week observational period.
For some subjects it was witnessed that the ones with a weight of approximately 233 pounds and a body mass index of 37, had a weight loss of 6%. The trial was followed by 12-week program to authenticate the results.
Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said, "This trial showed it was possible to achieve both clinically significant weight loss and excellent glucose control with a single treatment in patients with type 2 diabetes".
Since he was elected the President of France on 7th...Read More
Following up on an unprecedented press release by...Read More
The French people are used to the presidential...Read More
Newly elected French President Emmanuel Macron said...Read More
At 39 years of age, Emmanuel Macron is the bold,...Read More